TEST:

LymphoTrack® Dx IGK Assay

Samples derived from cases from both the experimental and the control arm, based respectively on ponatinib followed by blinatumomab and on a combination of imatinib and conventional chemotherapy. While some groups reported a higher predictive prognostic power of IG/TR monitoring, our findings do not confirm these data, also in view of the very low rate of relapses so far observed. Nevertheless, a double-hit strategy may be informative for MRD monitoring and possibly for the distinction between typical/lymphoid Ph+ ALL vs multilineage/CML-like Ph+ ALL.

Overall, NGS of the vitreous demonstrated high sensitivity among conventional diagnostic tests. VRL and CNSL appeared to have both shared and distinct genetic variations, which may suggest site-specific variations from a common origin.

A multicenter cohort of 53 consecutive newly diagnosed DLBCL treated with R-CHOP was included in this study... In most DLBCL patients at diagnosis, ctDNA was suitable for IG-based biomarker identification by NGS and was comparable to diagnostic LN biopsies. ctDNA MRD evaluation both at interim and at EOT allowed to predict theoutcome of DLBCL patients. ctDNA MRD can refine the CT/PET-CT-based response.

"Our study demonstrated that MRD assessment by NGS-based Ig clonality assay could be applied in most pediatric B-ALL patients. Normalized post-induction MRD <0.01% was a significant prognostic indicator."